Structural requirements for the collagenase and elastase activity of cathepsin K and its selective inhibition by an exosite inhibitor

Biochemical Journal

Volumn 465, Issue , 2015, Pages 163-173

  Sharma, Vidhu ^a   Panwar, Preety ^a   O'Donoghue, Anthony J ^b   Cui, Haoran ^a   Guido, Rafael V C ^c   Craik, Charles S ^b   Brömme, Dieter ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cathepsin K; Collagen; Collagenase; Elastase; Elastin; Exosite

Indexed keywords

CATHEPSIN K; CATHEPSIN S; CATHEPSIN V; COLLAGENASE; ELASTASE; ELASTIN; ELEMENT; COLLAGEN; MUTANT PROTEIN; PANCREATIC ELASTASE; PROTEIN BINDING; PROTEINASE INHIBITOR;

ARTICLE; COLLAGEN DEGRADATION; COLLAGEN FIBER; DRUG TARGETING; ELASTOLYSIS; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PURIFICATION; ENZYME STABILITY; ENZYME STRUCTURE; HUMAN; IC50; MOLECULAR DOCKING; MOLECULAR WEIGHT; OSTEOPOROSIS; PROTEIN MODIFICATION; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; BOVINAE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; EXTRACELLULAR MATRIX; KINETICS; METABOLISM; MOLECULAR GENETICS; PROTEIN DEGRADATION; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; CATALYTIC DOMAIN; CATHEPSIN K; CATTLE; COLLAGEN; COLLAGENASES; EXTRACELLULAR MATRIX; HUMANS; KINETICS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTANT PROTEINS; PANCREATIC ELASTASE; PROTEASE INHIBITORS; PROTEIN BINDING; PROTEOLYSIS; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 84918586752     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20140809     Document Type: Article

References (50)

1. Yasuda, Y., Li, Z., Greenbaum, D., Bogyo, M., Weber, E. and Brömme, D. (2004) Cathepsin V, a novel and potent elastolytic activity expressed in activated macrophages. J. Biol. Chem. 279, 36761-36770 CrossRef PubMed
2. Brömme, D. (2011) Cystein cathepsins and the skeleton. Clin. Rev. Bone Miner. Metab. 9, 83-93 CrossRef
3. Fonovic, M. and Turk, B. (2014) Cysteine cathepsins and extracellular matrix degradation. Biochim. Biophys. Acta 1840, 2560-2570 CrossRef PubMed
4. Kiviranta, R., Morko, J., Uusitalo, H., Aro, H. T., Vuorio, E. and Rantakokko, J. (2001) Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K. J. Bone Miner. Res. 16, 1444-1452 CrossRef PubMed
5. Yasuda, Y., Kaleta, J. and Brömme, D. (2005) The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv. Drug Deliv. Rev. 57, 973-993 CrossRef PubMed
6. Lutgens, S. P., Cleutjens, K. B., Daemen, M. J. and Heeneman, S. (2007) Cathepsin cysteine proteases in cardiovascular disease. FASEB J. 21, 3029-3041 CrossRef PubMed
7. Sukhova, G. K. and Shi, G. P. (2006) Do cathepsins play a role in abdominal aortic aneurysm pathogenesis? Ann. N. Y. Acad. Sci. 1085, 161-169 CrossRef
8. Brömme, D. and Lecaille, F. (2009) Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opin. Investig. Drugs 18, 585-600 CrossRef PubMed
9. Brömme, D., Okamoto, K., Wang, B. B. and Biroc, S. (1996) Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts. Functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme. J. Biol. Chem. 271, 2126-2132 CrossRef PubMed
10. Bossard, M. J., Tomaszek, T. T., Thompson, S. K., Amegadzies, B. Y., Hannings, C. R., Jones, C., Kurdyla, J. T., McNulty, D. E., Drake, F. H., Gowen, M. and Levy, M. A. (1996) Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification. J. Biol. Chem. 271, 12517-12524 CrossRef PubMed
11. Samokhin, A. O., Wong, A., Saftig, P. and Brömme, D. (2008) Role of cathepsin K in structural changes in brachiocephalic artery during progression of atherosclerosis in apoE-deficient mice. Atherosclerosis 200, 58-68 CrossRef PubMed
12. Podgorski, I. (2009) Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis? Future Med. Chem. 1, 21-34 PubMed
13. Chapurlat, R. D. (2014) Odanacatib for the treatment of postmenopausal osteoporosis. Expert Opin. Pharmacother. 15, 97-102 CrossRef PubMed
14. Tepel, C., Brömme, D., Herzog, V. and Brix, K. (2000) Cathepsin K in thyroid epithelial cells: sequence, localization and possible function in extracellular proteolysis of thyroglobulin. J. Cell Sci. 113, 4487-4498 PubMed
15. Zhang, D., Leung, N., Weber, E., Saftig, P. and Brömme, D. (2011) The effect of cathepsin K deficiency on airway development and TGF-β1 degradation. Respir. Res. 12, 72 CrossRef PubMed
16. Godat, E., Lecaille, F., Desmazes, C., Duchene, S., Weidauer, E., Saftig, P., Brömme, D., Vandier, C. and Lalmanach, G. (2004) Cathepsin K: a cysteine protease with unique kinin-degrading properties. Biochem. J. 383, 501-506 CrossRef PubMed
17. Lendeckel, U., Kahne, T., Ten Have, S., Bukowska, A., Wolke, C., Bogerts, B., Keilhoff, G. and Bernstein, H. G. (2009) Cathepsin K generates enkephalin from beta-endorphin: a new mechanism with possible relevance for schizophrenia. Neurochem. Int. 54, 410-417 CrossRef PubMed
18. Buhling, F., Rocken, C., Brasch, F., Hartig, R., Yasuda, Y., Saftig, P., Brömme, D. and Welte, T. (2004) Pivotal role of cathepsin K in lung fibrosis. Am. J. Pathol. 164, 2203-2216 CrossRef PubMed
19. Dauth, S., Sirbulescu, R. F., Jordans, S., Rehders, M., Avena, L., Oswald, J., Lerchl, A., Saftig, P. and Brix, K. (2011) Cathepsin K deficiency in mice induces structural and metabolic changes in the central nervous system that are associated with learning and memory deficits. BMC Neurosci. 12, 74 CrossRef PubMed
20. Rajan, N., Habermehl, J., Cote, M. F., Doillon, C. J. and Mantovani, D. (2006) Preparation of ready-to-use, storable and reconstituted type I collagen from rat tail tendon for tissue engineering applications. Nat. Protoc. 1, 2753-2758 CrossRef PubMed
21. Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K. et al. (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47, 1739-1749 CrossRef PubMed
22. Halgren, T. A., Murphy, R. B., Friesner, R. A., Beard, H. S., Frye, L. L., Pollard, W. T. and Banks, J. L. (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem. 47, 1750-1759 CrossRef PubMed
23. Dossetter, A. G., Beeley, H., Bowyer, J., Cook, C. R., Crawford, J. J., Finlayson, J. E., Heron, N. M., Heyes, C., Highton, A. J., Hudson, J. A. et al. (2012) (1R,2R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritis. J. Med. Chem. 55, 6363-6374 CrossRef PubMed
24. Friesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., Sanschagrin, P. C. and Mainz, D. T. (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 49, 6177-6196 CrossRef PubMed
25. Du, X., Chen, N. L., Wong, A., Craik, C. S. and Brömme, D. (2013) Elastin degradation by cathepsin V requires two exosites. J. Biol. Chem. 288, 34871-34881 CrossRef PubMed
26. Panwar, P., Du, X., Sharma, V., Lamour, G., Castro, M., Li, H. and Brömme, D. (2013) Effects of cysteine proteases on the structural and mechanical properties of collagen fibers. J. Biol. Chem. 288, 5940-5950 CrossRef PubMed
27. Hou, W. S., Li, Z., Buttner, F. H., Bartnik, E. and Brömme, D. (2003) Cleavage site specificity of cathepsin K toward cartilage proteoglycans and protease complex formation. Biol. Chem. 384, 891-897 CrossRef PubMed
28. Novinec, M., Grass, R. N., Stark, W. J., Turk, V., Baici, A. and Lenarcic, B. (2007) Interaction between human cathepsins K, L, and S and elastins: mechanism of elastinolysis and inhibition by macromolecular inhibitors. J. Biol. Chem. 282, 7893-7902 CrossRef PubMed
29. Bhaskaran, R., Palmier, M. O., Lauer-Fields, J. L., Fields, G. B. and Van Doren, S. R. (2008) MMP-12 catalytic domain recognizes triple helical peptide models of collagen V with exosites and high activity. J. Biol. Chem. 283, 21779-21788 CrossRef PubMed
30. Fulcher, Y. G. and Van Doren, S. R. (2011) Remote exosites of the catalytic domain of matrix metalloproteinase-12 enhance elastin degradation. Biochemistry 50, 9488-9499 CrossRef PubMed
31. Li, Z., Hou, W. S., Escalante-Torres, C. R., Gelb, B. D. and Brömme, D. (2002) Collagenase activity of cathepsin K depends on complex formation with chondroitin sulfate. J. Biol. Chem. 277, 28669-28676 CrossRef PubMed
32. Li, Z., Kienetz, M., Cherney, M. M., James, M. N. and Brömme, D. (2008) The crystal and molecular structures of a cathepsin K:chondroitin sulfate complex. J. Mol. Biol. 383, 78-91 CrossRef PubMed
33. Cherney, M. M., Lecaille, F., Kienitz, M., Nallaseth, F. S., Li, Z., James, M. N. and Brömme, D. (2011) Structure-activity analysis of cathepsin K/chondroitin 4-sulfate interactions. J. Biol. Chem. 286, 8988-8998 CrossRef PubMed
34. Gelb, B. D., Brömme, D. and Desnick, R. J. (2001) Pycnodysostosis: cathepsin K deficiency. In The Metabolic and Molecular Bases of Inherited Diseases (Sriver, C. R., Beaudet, A. L., Valle, D. and Sly, W. C. S., eds), vol. III, part 16, pp. 3453-3468, McGraw-Hill
35. Hou, W.-S., Brömme, D., Zhao, Y., Mehler, E., Dushey, C., Weinstein, H., Miranda, C. S., Fraga, C., Greig, F., Carey, J. et al. (1999) Cathepsin K: characterization of novel mutations in the pro and mature polypeptide regions causing pycnodysostosis. J. Clin. Invest. 103, 731-738 CrossRef PubMed
36. Overall, C. M. (2001) Matrix metalloproteinase substrate binding domains, modules and exosites. Overview and experimental strategies. Methods Mol. Biol. 151, 79-120 PubMed
37. Bertini, I., Fragai, M., Luchinat, C., Melikian, M., Toccafondi, M., Lauer, J. L. and Fields, G. B. (2012) Structural basis for matrix metalloproteinase 1-catalyzed collagenolysis. J. Am. Chem. Soc. 134, 2100-2110 CrossRef PubMed
38. Manka, S. W., Carafoli, F., Visse, R., Bihan, D., Raynal, N., Farndale, R. W., Murphy, G., Enghild, J. J., Hohenester, E. and Nagase, H. (2012) Structural insights into triple-helical collagen cleavage by matrix metalloproteinase 1. Proc. Natl. Acad. Sci. U.S.A. 109, 12461-12466 CrossRef PubMed
39. Fields, G. B. (2013) Interstitial collagen catabolism. J. Biol. Chem. 288, 8785-8793 CrossRef PubMed
40. Stura, E. A., Visse, R., Cuniasse, P., Dive, V. and Nagase, H. (2013) Crystal structure of full-length human collagenase 3 (MMP-13) with peptides in the active site defines exosites in the catalytic domain. FASEB J. 27, 4395-4405 CrossRef PubMed
41. Lecaille, F., Choe, Y., Brandt, W., Li, Z., Craik, C. S. and Bromme, D. (2002) Selective inhibition of the collagenolytic activity of human cathepsin K by altering its S2 subsite specificity. Biochemistry 41, 8447-8454 CrossRef PubMed
42. Bannwarth, L., Goldberg, A. B., Chen, C. and Turk, B. E. (2012) Identification of exosite-targeting inhibitors of anthrax lethal factor by high-throughput screening. Chem. Biol. 19, 875-882 CrossRef PubMed
43. Wang, W., Liu, Y. and Lazarus, R. A. (2013) Allosteric inhibition of BACE1 by an exosite-binding antibody. Curr. Opin. Struct .Biol. 23, 797-805 CrossRef PubMed
44. Costa, A. G., Cusano, N. E., Silva, B. C., Cremers, S. and Bilezikian, J. P. (2011) Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat. Rev. Rheumatol. 7, 447-456 CrossRef PubMed
45. Cui, L., Wu, T., Liu, Y. Y., Deng, Y. F., Al, C. M. and Chen, H. Q. (2004) Tanshinone prevents cancellous bone loss induced by ovariectomy in rats. Acta Pharmacol. Sin. 25, 678-684 PubMed
46. Kim, H. H., Kim, J. H., Kwak, H. B., Huang, H., Han, S. H., Ha, H., Lee, S. W., Woo, E. R. and Lee, Z. H. (2004) Inhibition of osteoclast differentiation and bone resorption by tanshinone IIA isolated from Salvia miltiorrhiza Bunge. Biochem. Pharmacol. 67, 1647-1656 CrossRef PubMed
47. Kim, H. K., Woo, E. R., Lee, H. W., Park, H. R., Kim, H. N., Jung, Y. K., Choi, J. Y., Chae, S. W., Kim, H. R. and Chae, H. J. (2008) The correlation of Salvia miltiorrhiza extract-induced regulation of osteoclastogenesis with the amount of components tanshinone I, tanshinone IIA, cryptotanshinone, and dihydrotanshinone. Immunopharmacol. Immunotoxicol. 30, 347-364 CrossRef PubMed
48. Xu, S., Little, P. J., Lan, T., Huang, Y., Le, K., Wu, X., Shen, X., Huang, H., Cai, Y., Tang, F., Wang, H. and Liu, P. (2011) Tanshinone II-A attenuates and stabilizes atherosclerotic plaques in apolipoprotein-E knockout mice fed a high cholesterol diet. Arch. Biochem. Biophys. 515, 72-79 CrossRef PubMed
49. Guo, Y., Li, Y., Xue, L., Severino, R. P., Gao, S., Niu, J., Qin, L. P., Zhang, D. and Brömme, D. (2014) Salvia miltiorrhiza : An ancient Chinese herbal medicine as a source for anti-osteoporotic drugs. J. Ethnopharmacol. 155, 1401-1416 CrossRef PubMed
50. Novinec, M., Korenc, M., Caflisch, A., Ranganathan, R., Lenarcic, B. and Baici, A. (2014) A novel allosteric mechanism in the cysteine peptidase cathepsin K discovered by computational methods. Nat. Commun. 5, 3287 CrossRef PubMed